Pfizer Inc. reported stronger-than-expected earnings, driven in part by sales of its COVID-19 treatment, Paxlovid. The company raised its guidance for future performance, indicating ongoing demand for its COVID-related products. Analysts noted that while the results exceeded prior expectations, they also highlighted the volatility in the market and the challenges in making accurate predictions about future performance. Goldman Sachs analyst Chris Shibutani remarked on the unpredictability of the current landscape, suggesting that Pfizer's results reflect a continued uncertainty in the sector. Despite the positive earnings report, some analysts expressed skepticism about the market's reaction to Pfizer's performance.